<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113955</url>
  </required_header>
  <id_info>
    <org_study_id>S2382</org_study_id>
    <nct_id>NCT03113955</nct_id>
  </id_info>
  <brief_title>STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</brief_title>
  <official_title>A Single-arm Trial of Transcatheter Arterial Chemoembolization With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in
      the Treatment of Localized Hepatocellular Carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, single-arm, multicenter study. The primary effectiveness endpoint for
      this clinical trial is 6-month overall objective tumor response (ORR).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>The objective response rate measured by MRI, CT, RECIST v 1.1 and mRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>TTP is measured by RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>Tumor Response is measured by MRI, CT , RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Progression-Free</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>PPF is measured by MRI, CT , RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>Overall survival is measured by RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events rate</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>documentation of all adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Localized Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>single -arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tandem Microsphere loaded with Epirubicin</intervention_name>
    <description>The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
    <arm_group_label>single -arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is able to provide informed consent and must sign the Institutional Review
             Board/Ethics Committee (IRB/EC) approved Informed Consent Form.

          2. Male or female of age ≥18 and ≤75 years.

          3. Confirmed diagnosis of HCC according to the diagnostic criteria included in the
             management guideline issued by China's Ministry of Health in 2017.

          4. HCC is diagnosed for the first time or recurrence of tumor after surgical or ablation
             treatment.

          5. Single tumor less than 7cm in diameter or multiple tumors with maximum 3 lesions with
             &gt;1cm in diameter, individual diameter &lt;7cm and less than 10cm in total diameter.

          6. no previous chemotherapy, radiotherapy or transarterial embolization (with or without
             chemotherapy) for HCC

          7. Preserved liver function (Child-Pugh A or B7).

          8. ECOG Performance Status 0 or 1.

        Exclusion Criteria:

          1. Presence of vascular invasion or extra-hepatic spread of disease, or diffuse HCC,
             defined as &gt;50% liver involvement , or arteriovenuous fistula

          2. Macrovascular invasion of main or primary branches of portal vein at entry into the
             study

          3. Any contraindication for TACE treatment

          4. Any contraindication for Epirubicin administration

          5. Advanced liver disease (bilirubin levels &gt;2 mg/dl, AST or ALT &gt;5 times upper limit of
             normal)

          6. Renal failure or insufficient renal function (Creatinine levels &gt;2 mg/dl)

          7. Subject unable to receive MRI examination

          8. Pregnant or breast feeding woman, or plan to become pregnant during treatment or
             within 12 months of treatment

          9. couldn't commit reliable birth control measures during treatment or within 12 months
             of treatment

         10. Subject is participating other investigational drug or device clinical trial within 30
             days of signing the informed consent

         11. Subject is not suitable to participate in the study as judged by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Peng</last_name>
    <role>Study Director</role>
    <affiliation>BSC China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Affiliated Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Affiliated China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Aff. Hosp. of Zhejiang University College of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

